- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The ...

Core Insights - Helius Medical Technologies has received reimbursement approval for the PoNS Device from United Healthcare, marking it as the second major healthcare provider to do so after Anthem [1][2] - The approved reimbursement amount totals $18,100, which reflects the out-of-network adjusted list price [2] Company Overview - Helius Medical Technologies is a neurotech company focused on addressing neurologic deficits through its Portable Neuromodulation Stimulator (PoNS) [3] - The PoNS device is designed to improve balance and gait deficits, particularly in patients with multiple sclerosis (MS) [4] Product Details - The PoNS Device is a non-implantable therapy that delivers neurostimulation via a mouthpiece, intended for use alongside physical rehabilitation exercises [4] - It is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms and is prescribed for patients aged 22 and older [4] Clinical Validation - The PoNS Device has demonstrated effectiveness in treating gait and balance issues, significantly reducing fall risks in stroke patients in Canada [5] - It has received authorization for multiple indications in Canada and is also approved for use in Australia [5]